Use of Highly Active Antiretroviral Therapy in a Cohort of HIV-Seropositive Women
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Author
Cook, Judith A.Cohen, Mardge H.
Grey, Dennis
Kirstein, Lynn
Burke, Jane
Anastos, Kathryn
Palacio, Herminia
Richardson, Jean
Wilson, Tracey E.
Young, Mary
Journal title
American Journal of Public HealthDate Published
2002-01Publication Volume
92Publication Issue
1Publication Begin page
82Publication End page
87
Metadata
Show full item recordAbstract
Objectives: This study examined longitudinal trends in use of highly active antiretroviral therapy (HAART) among a cohort of HIV-positive participants in the Women' Interagency HIV Study. Methods: Beginning in 1994, 1690 HIV-positive women reported detailed information about their use of antiretroviral therapy at 6-month study visits. Multivariate logistic and Cox regression analyses were used to estimate the likelihood of antiretroviral therapy and HAART use among women with study visits preceding and following HAART availability. Results: Before the availability of HAART, the cohort' likelihood of any antiretroviral therapy use was associated with clinical indicators (CD4 count, viral load, symptom presence) as well as behavioral factors (abstaining from drug and alcohol use, participating in clinical trials). After HAART became commercially available, newly emerging predictors included college education, private insurance, absence of injection drug use history, and not being African American. Conclusions: After the penetration of HAART into this cohort, additional differences emerged between HAART users and nonusers. These findings can inform public health efforts to enhance women' access to the most effective types of therapy.Citation
Cook JA, Cohen MH, Grey D, Kirstein L, Burke J, Anastos K, Palacio H, Richardson J, Wilson TE, Young M. Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am J Public Health. 2002 Jan;92(1):82-7. doi: 10.2105/ajph.92.1.82. PMID: 11772767; PMCID: PMC1447394.DOI
10.2105/ajph.92.1.82ae974a485f413a2113503eed53cd6c53
10.2105/ajph.92.1.82
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
Related articles
- Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women.
- Authors: Cook JA, Cohen MH, Burke J, Grey D, Anastos K, Kirstein L, Palacio H, Richardson J, Wilson T, Young M
- Issue date: 2002 Aug 1
- Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
- Authors: Jaspan HB, Berrisford AE, Boulle AM
- Issue date: 2008 Nov
- Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS).
- Authors: Navazesh M, Mulligan R, Karim R, Mack WJ, Ram S, Seirawan H, Greenspan J, Greenspan D, Phelan J, Alves M, Oral Substudy of the Women's Interagency HIV Study Collaborative Study Group*
- Issue date: 2009 Jan
- HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
- Authors: Pham QD, Huynh TK, Luong TT, Tran T, Vu TX, Truong LX
- Issue date: 2013 Jan-Feb
- Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor.
- Authors: Calista D, Morri M, Stagno A, Boschini A
- Issue date: 2002